, a condition where a person’s arms or legs don’t receive enough blood to keep up with what they need. Severe cases of this disease can lead to strokes and heart attacks or to a condition called, which can have an extremely high mortality rate if the limb is not amputated. When this disease impacts the lower legs, the standard of care is balloon angioplasty, which can be helpful but is not sustainable.
“This was the first trial to show that there was a therapy that can exceed what is offered to patients,” Jennifer Jones-McMeans, Abbot’s VP of global clinical affairs, told“It leaves so much opportunity for patients and physicians to have a new tool to combat this disease.
A startup called Gordian Biotechnology has debuted a technology that could make this process better for both animals and people:a new animal screening platform which allows multiple gene therapies to be tested at the same time with just one animal. Instead of the gene treatment being given to the animal and affecting an entire area of its body, Gordian’s innovation enables it to test a drug inside of a single cell.
“We’ve got a platform that allows us to essentially parallelize the hardest part of the drug discovery process, the animal testing process,” Gordian CEO Francisco LePort told Forbes.Medtronic’s Inceptiv spinal cord stimulator for chronic pain treatment. What’s different about Medtronic’s new system is that it’s capable of sensing a patient’s body position and adjusts the amount of electrical stimulation accordingly, improving quality of life.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Danicopan as Add-On Therapy for Hemolysis TreatmentThe US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab orPNH is a rare blood disorder affecting 1-10 individuals per million. The condition, which eliminates red blood cells and leads to blood clots and impaired bone marrow function, can cause life-threateningRavulizumab and eculizumab, also both made by AstraZeneca, inhibit the destruction of red blood cells. However, 10%-20% of patients treated with the antibody infusions experience significant extravascular hemolysis, in which these surviving red blood cells are eliminated by the spleen and liver. Extravascular hemolysis can lead to ongoing anemia, which can lead patients to require blood transfusions. Danicopan, an investigational, first-in-class, oral complement factor D inhibitor, is designed to control intravascular hemolysis and prevent extravascular hemolysis
Source: Medscape - 🏆 386. / 55 Read more »
FDA Approves TriClip for Tricuspid RegurgitationThe FDA has approved the use of TriClip for the treatment of tricuspid regurgitation. The decision was based on the results of a randomized controlled trial, which showed that patients who underwent repair with the TriClip system experienced a significant reduction in valve dysfunction and improvement in quality of life. The procedure was found to be safe, with a low rate of major adverse events.
Source: Medscape - 🏆 386. / 55 Read more »
FDA Approves Iloperidone for Bipolar DisorderThe US Food and Drug Administration has approved iloperidone tablets (Fanapt) for the treatment of bipolar disorder in adults.
Source: Medscape - 🏆 386. / 55 Read more »
FDA Approves Iloperidone for Bipolar I DisorderThe FDA has approved iloperidone for the treatment of bipolar I disorder based on positive results from a phase 3 trial. Patients treated with iloperidone showed significant improvement in symptoms compared to those who received a placebo.
Source: Medscape - 🏆 386. / 55 Read more »
FDA Approves Basilea Pharmaceutica's Antibiotic for Multidrug-Resistant Bacterial InfectionsThe U.S. health regulator approved Basilea Pharmaceutica's antibiotic for bacterial infections including multidrug-resistant strains, expanding treatment options for patients. The antibiotic, ceftobiprole, will be sold under the brand name Zevtera in the U.S.
Source: Investingcom - 🏆 450. / 53 Read more »